Takaisin Tulosta

Hormonal contraception in overweight or obese women

Evidence summaries
Editors
16.12.2017

Level of evidence: D

Overweight might possibly not affect the effectiveness of hormonal contraception, but the evidence is insufficient. However, risk of venous thromboembolism may be 5 to 8 times higher in obese combined oral contraceptive (COC) users compared to obese nonusers.

A Cochrane review «»1 «Lopez LM, Grimes DA, Chen-Mok M, Westhoff C, Edelm...»1 included 9 reports with data from 17 trials involving a total of 63 813 subjects. Most studies did not show a higher pregnancy risk among overweight or obese women. One of 5 studies using BMI found a higher pregnancy risk for overweight or obese women. In that trial, women assigned to an oral contraceptive (COC) containing norethindrone acetate 1.0 mg plus EE 20 µg and having a BMI at least 25 had greater pregnancy risk compared to those with BMI less than 25 (reported RR 2.49; 95% CI 1.01 to 6.13). The comparisons reported in the other 4 studies were not significantly different for pregnancy. A trial using a COC with levonorgestrel and EE reported a Pearl Index of 0 for obese women (BMI ≥ 30) versus 5.59 for nonobese women (BMI < 30). The same trial tested a transdermal patch containing levonorgestrel and EE. Within the patch group, obese women in the "treatment-compliant" subgroup had a higher reported Pearl Index than nonobese women (4.63 versus 2.15). Four studies from the 1990s used weight alone rather than BMI. Results were mixed. Among skin patch users, body weight was associated with pregnancy (reported P < 0.001) but BMI was not. Of 5 implant studies, 2 that examined the six-capsule levonorgestrel implant showed differences in pregnancy by weight. One study showed higher weight was associated with higher pregnancy rate in years 6 and 7 combined (reported P < 0.05). In the other, pregnancy rates differed in year 5 among the lower weight groups only (reported P < 0.01) and did not involve women weighing 70 kg or more. However, the groups of overweight women were smaller than groups of women with normal weigth in all studies.

A systematic review «...»2 evaluated risk of acute myocardial infarction (AMI), stroke, cerebral venous thrombosis (CVT) and venous thromboembolism (VTE) in obese women using combined hormonal contraception including 3 pooled analyses, 11 case-control studies and 1 cohort study. One study showed no increased risk for AMI or stroke for COC users overall or stratified by BMI, another study found significantly increased risk of AMI and stroke, with the highest risk estimates for high-BMI COC users. A single study suggested that obese COC users may be at higher risk for CVT compared with normal-weight nonusers. For VTE, obese COC users consistently had a risk that was 5 to 8 times that of obese nonusers and approximately 10 times that of nonobese nonusers. 5 prospective cohort studies were identified as indirect evidence, and all found increased risk for VTE as BMI increased, suggesting a dose-response relationship between BMI and risk for VTE.

Comment: The quality of evidence is downgraded by study quality (post-hoc analysis and other shortcomings) and by inconsistency (variability in results across studies).

References

  1. Lopez LM, Grimes DA, Chen-Mok M, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2010 Jul 7;(7):CD008452 [Review content assessed as up-to-date: 4 August 2016]. «PMID: 20614470»PubMed
  2. Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception 2016;94(6):590-604. «PMID: 27263039»PubMed